Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance disclosures regarding director shareholdings.
Material Changes
On December 31, 2013, Non-Executive Directors were allocated notional Ordinary Shares at a price of £16.07 per share and notional American Depositary Shares (ADSs) at $53.17 per ADS. These allocations covered the service period from October 1, 2013, to December 31, 2013. The Company and Directors were informed of these allocations on January 2, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Allocation date: December 31, 2013.
- Share price basis: £16.07 per Ordinary Share and $53.17 per ADS.
- Service period covered: October 1, 2013, to December 31, 2013.
- Notification date to Directors: January 2, 2014.
- Specific allocations were made to 12 Non-Executive Directors, including Sir Christopher Gent, Professor Sir Roy Anderson, and Judy Lewent.